BeiGene, Ltd. (ONC)vsSoleno Therapeutics Inc (SLNO)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
SLNO
Soleno Therapeutics Inc
$31.84
+1.60%
HEALTHCARE · Cap: $1.68B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 2706% more annual revenue ($5.34B vs $190.41M). SLNO leads profitability with a 11.0% profit margin vs 5.4%. SLNO trades at a lower P/E of 80.4x. SLNO earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
SLNO
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Margin of Safety
-1411.3%
Fair Value
$2.65
Current Price
$31.84
$29.19 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Strong operational efficiency at 44.1%
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : SLNO
The strongest argument for SLNO centers on Operating Margin.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : SLNO
The primary concerns for SLNO are Revenue Growth, EPS Growth, Altman Z-Score. A P/E of 80.4x leaves little room for execution misses.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while SLNO is a value play — different risk/reward profiles.
ONC carries more volatility with a beta of 0.52 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 42/100) and 32.8% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Soleno Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?